Ticker Hub
ROIV — AI Analysis & Sentiment
3 recent AI-generated analyses for ROIV. Sentiment and confidence insights updated continuously.
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Roivant's recent earnings reveal a strong financial position, driven by a major legal settlement and promising clinical pipeline developments, sign...
May 20, 2026Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
The $2.25 billion settlement with Moderna provides Roivant significant cash inflow and validates its IP portfolio.
Mar 3, 2026Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Priovant announced FDA acceptance of its drug application for brepocitinib, which could be a breakthrough treatment for dermatomyositis. This is si...
Mar 3, 2026